CEO, William V. Williams, Reveals Game-Changing Partnership and Innovative Breakthroughs in Targeted Immunotherapies for Cancer Treatment

NEW YORK, NY - (NewMediaWire) - May 31, 2023 - BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT), a clinical-stage biotechnology company focused on targeted immunotherapies for cancer, is pleased to announce that its President and CEO, William V. Williams, recently conducted an interview with SmallCapsDaily. During the interview, Mr. Williams discussed BriaCell's exciting and recent collaboration with Prevail Partners and Prevail Infoworks, as well as the Company's innovative strategy for cancer treatment.

Dr. Williams is a seasoned biopharma executive with over 35 years of industry and academic expertise, including significant clinical management in multinational pharmaceutical companies. Dr. Williams has served as BriaCell’s President & CEO since Oct 2016. Previously, Dr. Williams was appointed as VP of Exploratory Development at Incyte Corporation during 2005 – 2016. He facilitated entry of over 20 compounds into the clinic, including approvals for ruxolitinib (Jakafi) and baricitinib (Olumiant).As VP of Clinical Pharmacology and Experimental Medicine.

To read the full interview visit: https://smallcapsdaily.com/interview-briacell-ceo-william-williams-md

About BriaCell Therapeutics Corp.

BriaCell is an immuno-oncology focused biotechnology company developing targeted and effective approaches for the management of cancer.

More information is available at https://briacell.com/.

For more information, please contact:

Small Caps Daily

info@smallcapsdaily.com

View the original release on www.newmediawire.com